PUMA BIOTECHNOLOGY, INC.
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
Puma Biotechnology is a biopharmaceutical company that markets Nerlynx (neratinib), an oral drug for treating certain forms of HER2-positive breast cancer, and conducts clinical development of additional cancer treatments.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| MILLER MICHAEL PATRICKDirector | Sell | $121K | 15,000at $8.10 | Nov 11, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable PBYI activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.